Switching prescription drugs to over the counter

doi:10.1136/bmj.330.7481.39

BMJ 2005;330:39-41 (1 January), doi:10.1136/bmj.330.7481.39

Education and debate

Switching prescription drugs to over the counter

Joshua P Cohen, senior research fellow¹, Cherie Paquette, research coordinator¹, Catherine P Cairns, research coordinator¹

¹ Tufts Center for the Study of Drug Development, Tufts University School of Medicine, 192 South Street, Suite 550, Boston MA 02111, USA

Correspondence to: J P Cohen joshua.cohen@tufts.edu

Appropriate self treatment is an important aspect of both theEuropean and American healthcare systems, but what is reallydriving increased over the counter availability?

The first 150 words of the full text of this article appear below.

Introduction

Increased numbers of prescription drugs are being made availableover the counter worldwide. Recent high profile switches haveincluded drugs in classes previously not eligible, such as omeprazolein Sweden and simvastatin in the United Kingdom. Switches aremotivated mainly by three factors: pharmaceutical firms' desireto extend the viability of brand names; attempts by healthcarefunders to contain costs; and the self care movement. Makingdrugs available over the counter affects a large number of stakeholders,including patients, pharmaceutical firms, physicians, pharmacists,drug regulatory agencies, and private and public health fundingorganisations. In this article, we illustrate the roles thatpharmaceutical firms, healthcare organisations, and governmentregulatory agencies played in three recent switches that havefuelled global debate: simvastatin in the United Kingdom, omeprazolein Sweden, and loratadine in the United States.

Simvastatin

Generally, a prescription drug becomes a candidate for overthe counter availability if it is used for . . . [Full text of this article]

Omeprazole

Loratadine

Effect of over the counter availability

US regulatory change

Future implications

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

StumbleUpon Add to Technorati

Technorati What's this?

This article has been cited by other articles:

(2009). The licensing of medicines in the UK. DTB 47: 45-47 [Abstract] [Full text]
Ferner, R. E, Beard, K. (2008). Over the counter medicines: proceed with caution. BMJ 336: 694-696 [Full text]
Gotto, A. M. Jr (2006). Over-The-Counter Statins Are Worth Considering in Primary Prevention of Cardiovascular Disease. Circulation 114: 1310-1314 [Full text]
Hird, M. (2005). Switching prescription drugs to over the counter: Chicken and egg scenario is possible. BMJ 330: 905-905 [Full text]
Bunney, R. G (2005). Switching prescription drugs to over the counter: Over the counter licensing is linked to direct to consumer advertising. BMJ 330: 906-906 [Full text]
Sullivan, P. W (2005). Switching prescription drugs to over the counter: Consumers may benefit financially in examples from the US. BMJ 330: 904-905 [Full text]
Quill, J., Martin, R. (2005). Switching prescription drugs to over the counter: Willingness to buy statin over the counter is not related to risk of heart disease. BMJ 330: 905-906 [Full text]
Duerden, M., Walley, T. (2005). Direct to consumer marketing: Switch to over the counter can become indirect advertising directly to consumers. BMJ 330: 906-906 [Full text]

Rapid Responses:

Read all Rapid Responses

What about Oseltamivir?: Gary D Lum
bmj.com, 31 Dec 2004 [Full text]
Motives differ between nations: Matthew Robinson
bmj.com, 1 Jan 2005 [Full text]
Chicken or Egg?: Magnus I Hird
bmj.com, 2 Jan 2005 [Full text]
The link between over the counter licensing and Direct to consumer advertising: Robert G Bunney
bmj.com, 4 Jan 2005 [Full text]
Ulterior: Dominic McDermott
bmj.com, 6 Jan 2005 [Full text]
Switching Drugs to OTC Status May Benefit Patients Financially: Patrick W. Sullivan
bmj.com, 11 Jan 2005 [Full text]
Changes to approved names of drugs: David R Hadden
bmj.com, 21 Apr 2005 [Full text]